Caniphedrin 50 mg Tablets for Dogs

Country: United Kingdom

Language: English

Source: VMD (Veterinary Medicines Directorate)

Active ingredient:

Ephedrine Hydrochloride

Available from:

Richter Pharma AG

ATC code:

QG04BX90

INN (International Name):

Ephedrine Hydrochloride

Pharmaceutical form:

Tablet

Prescription type:

POM-V - Prescription Only Medicine – Veterinarian

Therapeutic group:

Dogs

Therapeutic area:

Neurological Agent

Authorization status:

Authorized

Authorization date:

2020-08-05

Summary of Product characteristics

Revised: January 2023
AN: 02966/2022
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Caniphedrin 50 mg tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Ephedrine hydrochloride
50 mg
(equivalent to 41.0 mg Ephedrine)
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablets
White tablets with score line. The tablets can be divided into 2 equal
parts.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment
of
urinary
incontinence
caused
by
urethral
sphincter
mechanism
incompetence in ovariohysterectomised female dogs.
4.3
CONTRAINDICATIONS
Do not use in dogs with cardiovascular disease (i.e. cardiomyopathy,
tachycardic
arrhythmia, hypertension), hyperthyroidism, diabetes mellitus,
impaired renal function or
glaucoma.
Do
not
use
concurrently
with
halogenated
narcotics
such
as
halothane
or
methoxyflurane (see section 4.8).
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
It is not appropriate to use the product for the behavioural cause of
inappropriate
urination.
Revised: January 2023
AN: 02966/2022
Page 2 of 5
In bitches less than 1 year old the possibility of anatomical
disorders contributing to
incontinence should be considered prior to treatment.
It is important to identify any underlying disease causing
Polyuria/Polydipsia (PU/PD)
which may be falsely diagnosed as urinary incontinence.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
The dog’s cardiovascular functionality should be carefully assessed
before the start
of the treatment with the product and it should be periodically
monitored during the
treatment.
Special precautions to be taken by the person administering the
veterinary medicinal
product to animals
People with known hypersensitivity to ephedrine should avoid contact
with the
veterinary medicinal produc